on October 13, 2005
Published online before print October 13, 2005, doi: 10.1161/01.ATV.0000190608.28704.71
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 27, 2005
Accepted on September 30, 2005
Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins
Maria L. Urso ;
From the Department of Exercise Science (M.L.U., P.M.C.), University of Massachusetts, Amherst, Mass; the Division of Cardiology (P.D.T.), Henry Low Heart Center, Hartford Hospital, Hartford, Conn; and the Research Center for Genetic Medicine (D.H., E.P.H.), Children’s National Medical Center, Washington DC.
* To whom correspondence should be addressed. E-mail: Clarkson{at}excsci.umass.edu.
Objective--Statins are safe medications but have side effects including myalgia and rhabdomyolysis. How statins provoke muscle damage is not known, but this effect is exacerbated by exercise.
Methods and Results--Healthy subjects took Atorvastatin (80 mg/daily) or placebo for 4 weeks. Biopsies of both vastus lateralis muscles were performed 8 hours after eccentric exercise (known to result in muscle soreness and damage) of the left leg at baseline and the right leg after statin/placebo treatment. Gene expression was determined using Affymetrix GeneChips, and selected genes confirmed by polymerase chain reaction (qRT-PCR). Atorvastatin had little effect on gene expression at rest. When combined with exercise, 56 genes were differentially expressed with 18% involved in the ubiquitin proteasome pathway (UPP) and 20% involved in protein folding and catabolism, and apoptosis.
Conclusion--This is the first investigation to our knowledge to implicate involvement of the UPP in skeletal muscle in response to combined exercise and statin treatment, possibly explaining the onset of myalgia with exertion. Statins may alter the response of muscle to exercise stress by altering the action of the UPP, protein folding, and catabolism, disrupting the balance between protein degradation and repair.
Related Article:
- Mechanisms of Statin-Induced Myopathy: A Role for the Ubiquitin–Proteasome Pathway?
- M. John Chapman and Alain Carrie
Arterioscler Thromb Vasc Biol 2005 25: 2441-2444.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  P. Cao, J.-i. Hanai, P. Tanksale, S. Imamura, V. P. Sukhatme, and S. H. Lecker Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect FASEB J, September 1, 2009; 23(9): 2844 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Mallinson, D. Constantin-Teodosiu, J. Sidaway, F. R. Westwood, and P. L. Greenhaff Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J. Physiol., January 1, 2009; 587(1): 219 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Urso, A. G. Scrimgeour, Y.-W. Chen, P. D. Thompson, and P. M. Clarkson Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components J Appl Physiol, October 1, 2006; 101(4): 1136 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Chapman and A. Carrie Mechanisms of Statin-Induced Myopathy: A Role for the Ubiquitin-Proteasome Pathway? Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2441 - 2444. [Full Text] [PDF]
|
|